MRM MRM
Company Profile ↓Company Overview
MRM (MRM) is a publicly traded company listed on with a market capitalization of $7.12M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 15.9%, reflecting efficient use of shareholder capital.
Revenue has grown at a 15.3% CAGR over the past five years.
Trades at an undemanding P/E of 0.0.
Recent Developments
- Dec 2024 Revenue of $8.30B (+21.5% YoY); net profit $148.76M.
- Trailing 12 Months Year-on-year growth — revenue +21.6%, earnings +28.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 15.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 15.33% |
| 1 Year: | 21.55% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 28.91% |
Stock Price Performance
| 1 Year: | -29.61% |
| 6 Months: | -38.77% |
| 3 Months: | -25.50% |
| 1 Month: | -12.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.57 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 15.3% over 5 years.
CONS
- Trading 69.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| Revenue | 5.41B | 6.95B | 6.83B | 8.30B |
| Cost of Revenue | 3.99B | 5.05B | 5.26B | 6.05B |
| Gross Profit | 1.42B | 1.90B | 1.57B | 2.25B |
| Operating Expenses | 1.79B | 1.78B | 1.94B | 2.23B |
| Operating Income | -379.53M | 117.59M | -370.20M | 18.62M |
| EBITDA | -276.29M | 373.63M | 310.08M | 387.50M |
| Interest Expense | 11.95M | 9.80M | 36.87M | 49.74M |
| Pretax Income | -414.48M | 179.77M | 20.62M | 47.71M |
| Tax Provision | 576.25M | 30.81M | -94.43M | -90.48M |
| Net Income | -990.73M | 148.97M | 115.40M | 148.76M |
| Diluted EPS | -203.13 | 27.23 | 22.34 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| Total Assets | 5.75B | 6.75B | 6.85B | 8.09B |
| Current Assets | 1.38B | 2.36B | 1.76B | 2.71B |
| Cash & Equivalents | 370.62M | 605.45M | 106.35M | 329.40M |
| Inventory | 18.70M | 114.11M | 139.98M | 151.64M |
| Receivables | 312.30M | 534.69M | 621.87M | 1.36B |
| Total Liabilities | 5.96B | 6.81B | 6.63B | 6.90B |
| Current Liabilities | 3.20B | 3.64B | 3.56B | 4.18B |
| Long Term Debt | 746.59M | 1.15B | 1.05B | 764.20M |
| Total Debt | 2.79B | 3.23B | 3.65B | 3.96B |
| Total Equity | -208.34M | -59.38M | 210.88M | 933.27M |
| Shares Outstanding | 4.98M | 4.98M | 4.98M | 7.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| Operating Cash Flow | -557.23M | -685.70M | -631.74M | -1.33B |
| Investing Cash Flow | -83.94M | 580.44M | -328.58M | 361.39M |
| Financing Cash Flow | -427.95M | 340.10M | 461.21M | 1.19B |
| Capital Expenditure | -113.78M | -166.50M | -922.02M | -564.81M |
| Free Cash Flow | -671.01M | -852.20M | -1.55B | -1.90B |
| Net Change in Cash | -1.07B | 234.84M | -499.11M | 223.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| Gross Margin % | 26.2% | 27.4% | 23.0% | 27.1% |
| Operating Margin % | -7.0% | 1.7% | -5.4% | 0.2% |
| Net Margin % | -18.3% | 2.1% | 1.7% | 1.8% |
| ROE % | 475.5% | -250.9% | 54.7% | 15.9% |
| ROCE % | -14.8% | 3.8% | -11.3% | 0.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MRM
MEDIROM MOTHER Labs Expands Deployment of "REMONY®" Remote Health Monitoring System in JGSDF 8th Division
Additional Orders Triple Implementation Scale; "MOTHER Bracelet®" Enables Continuous Safety Monitoring During Extended Training TOKYO, June 25, 2026 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; President: Yo…
MEDIROM Group Reports Q1 2026 Results
TOKYO, May 28, 2026 (GLOBE NEWSWIRE) -- This report presents an overview of our business performance and key performance indicators (KPIs) for the first quarter of 2026 (January–March 2026). It also highlights trends over the past five quar…
Micromem Technologies Inc. Provides Update on Gas-Sensing Technology Development
Toronto, Ontario and New York, New York--(Newsfile Corp. - April 6, 2026) - Micromem Technologies Inc. (CSE: MRM) (OTCQB: MMTIF) ("Micromem" or the "Company") is pleased to provide an update on the gas-phase sensor path under its collaborat…
Micromem Technologies Inc. Provides Update on Liquid-Sensing Technology Development
Toronto, Ontario and New York, New York--(Newsfile Corp. - March 30, 2026) - Micromem Technologies Inc. (CSE: MRM) (OTCQB: MMTIF) ("Micromem" or the "Company") is pleased to provide an update on the liquid-phase sensor development within th…
MEDIROM Launches Partnership with Tools for Humanity in February; Projects Approximately $39 Million in Income Before Income Taxes Over Two Years Following Expansion to 3,000 Nationwide Locations
TOKYO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on the Nasdaq Capital Market: NASDAQ: MRM) announced that the Master Service Agreement (t…
MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity
TOKYO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on Nasdaq: NASDAQ: MRM, hereinafter “MEDIROM”), a company engaged in diversified healthca…
MRM — Frequently Asked Questions
What is the current share price of MRM?
As of 2026-08-05 17:25 PDT, MRM trades at $0.89 on NASDAQ/NYSE. Its 52-week range is $0.89 to $2.94.
What is the market capitalisation of MRM?
MRM has a market capitalisation of $7.12M on NASDAQ/NYSE.
What is the P/E ratio of MRM?
MRM trades at a trailing price-to-earnings (P/E) ratio of 0.04. Its price-to-book (P/B) ratio is 0.01.
What is the return on equity (ROE) of MRM?
MRM has a return on equity (ROE) of 15.94%. Its return on capital employed (ROCE) is 0.48%.
Is MRM a good stock to buy?
This page provides a data-driven analysis of MRM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.